The Bayer - Recursion Collaboration

The Bayer - Recursion collaboration brings together Recursion’s technology-forward and AI-leading emphasis and Bayer’s legacy of drug development. The $1.5B deal announced last October in precision oncology already has one joint project now rapidly advancing to Lead Series nomination and we are on track to complete 25 unique multimodal data packages in Q3 2024.
Bayer will be the first beta-user of Recursion's LOWE LLM-orchestrated workflow software, which will be integrated across the collaboration and offer a more exploratory and intuitive research environment for scientists on both sides.
About Recursion:
Recursion is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Central to its mission is the Recursion Operating System (OS), a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale-up to millions of wet lab experiments weekly-and massive computational scale-owning and operating one of the most powerful supercomputers in the world-Recursion is uniting technology, biology, chemistry and patient-centric data to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal, the San Francisco Bay Area and London.
Visit www.recursion.com to learn more.
#biology #chemistry #data #datascience #drugdiscovery #biotech #biotechnology #healthcare #health #medicine #ai #artificialintelligence #machinelearning #ml #techbio #cancer #oncology #pharma #llmexaminationform #partnership